Log in

NYSE:AZNAstraZeneca Stock Price, Forecast & News

$54.19
+0.72 (+1.35 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$53.62
Now: $54.19
$54.70
50-Day Range
$51.47
MA: $53.52
$55.28
52-Week Range
$36.15
Now: $54.19
$57.44
Volume6.25 million shs
Average Volume5.08 million shs
Market Capitalization$142.21 billion
P/E Ratio91.85
Dividend Yield3.48%
Beta0.55
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
AstraZeneca logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 1.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.38 billion
Cash Flow$3.21 per share
Book Value$5.56 per share

Profitability

Net Income$1.34 billion

Miscellaneous

Employees64,400
Outstanding Shares2,624,370,000
Market Cap$142.21 billion
Next Earnings Date7/30/2020 (Confirmed)
OptionableOptionable

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 21.6% and is now trading at $54.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AstraZeneca.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for AstraZeneca.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) announced its earnings results on Wednesday, April, 29th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.06. The business earned $6.35 billion during the quarter, compared to analyst estimates of $5.95 billion. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The firm's quarterly revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 EPS. View AstraZeneca's earnings history.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semi-annual dividend on Tuesday, February 18th. Shareholders of record on Friday, February 28th will be given a dividend of $0.95 per share on Monday, March 30th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 27th. View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

11 Wall Street analysts have issued 1 year price objectives for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they anticipate AstraZeneca's stock price to reach $61.67 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price. View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

Headlines about AZN stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about AstraZeneca.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AbbVie (ABBV), AT&T (T), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Bank of America (BAC) and Johnson & Johnson (JNJ).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.01%), Park National Corp OH (0.01%), Town & Country Bank & Trust CO dba First Bankers Trust CO (0.00%), Courier Capital LLC (0.00%), Private Trust Co. NA (0.00%) and First Financial Bank Trust Division (0.00%). View institutional ownership trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Private Trust Co. NA, Town & Country Bank & Trust CO dba First Bankers Trust CO, and Courier Capital LLC. View insider buying and selling activity for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Ellevest Inc., and First Financial Bank Trust Division. View insider buying and selling activity for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $54.19.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $142.21 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.